Related Party Transactions	9 Months Ended
Sep. 30, 2021
Related Party Transactions [Abstract]
Related Party Transactions	13. Related Party Transactions The Company entered into an agreement with ElevateBio that provides for ongoing services to the Company in areas such as accounting operations, public relations, information technology, human resources and administration management, finance and risk management, marketing services, facilities, procurement and travel and corporate development and strategy (the “Shared Services Agreement”). The Company was billed quarterly for such services at cost, with mark-up for profit on specific services, but including reasonable allocations of employee benefits, facilities and other direct or fairly allocated indirect costs that relate to the associates providing the services. The Company also subleases office space, which includes payment for common area charges. The Company also has a SOW to receive manufacturing and project management consulting services from ElevateBio. The Company incurred $0.6 million and $2.3 million during the three months ended September 30, 2021 and 2020, respectively, and $4.1 million and $4.8 million of expenses during the nine months ended September 30, 2021 and 2020, respectively, related to services provided to the Company by ElevateBio and affiliates. The Company owed ElevateBio $1.9 million and $0.6 million at September 30, 2021 and December 31, 2020, respectively, which is recorded in “Amount due to related party” on the condensed consolidated balance sheets. Members of the Company’s management received a total of $0.1 million in consulting fees during the three months ended September 30, 2021 and 2020 and $0.3 million and $0.5 million during the nine months ended September 30, 2021 and 2020, respectively.

Related Party Transactions

9 Months Ended

Sep. 30, 2021

13. Related Party Transactions

The Company entered into an agreement with ElevateBio that provides for ongoing services to the Company in areas such as accounting operations, public relations, information technology, human resources and administration management, finance and risk management, marketing services, facilities, procurement and travel and corporate development and strategy (the “Shared Services Agreement”). The Company was billed quarterly for such services at cost, with mark-up for profit on specific services, but including reasonable allocations of employee benefits, facilities and other direct or fairly allocated indirect costs that relate to the associates providing the services. The Company also subleases office space, which includes payment for common area charges. The Company also has a SOW to receive manufacturing and project management consulting services from ElevateBio. The Company incurred $0.6 million and $2.3 million during the three months ended September 30, 2021 and 2020, respectively, and $4.1 million and $4.8 million of expenses during the nine months ended September 30, 2021 and 2020, respectively, related to services provided to the Company by ElevateBio and affiliates. The Company owed ElevateBio $1.9 million and $0.6 million at September 30, 2021 and December 31, 2020, respectively, which is recorded in “Amount due to related party” on the condensed consolidated balance sheets.

Members of the Company’s management received a total of $0.1 million in consulting fees during the three months ended September 30, 2021 and 2020 and $0.3 million and $0.5 million during the nine months ended September 30, 2021 and 2020, respectively.